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Appendix A: STROBE 2007 Statement—Checklist of items that should be included in reports of cohort studies 
 
Section/Topic Item 
# 
Recommendation Reported on page # 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract Page 1 
(b) Provide in the abstract an informative and balanced summary of what was done and what was found Page 2 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported Page 3-4 
Objectives 3 State specific objectives, including any prespecified hypotheses Page 3-4 
Methods  
Study design 4 Present key elements of study design early in the paper Participants and 
Study Settings  
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Participants and 
Study Settings  
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Participants and 
Study Settings  
(b) For matched studies, give matching criteria and number of exposed and unexposed Not applicable 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if 
applicable 
Risk Factor 
Assessment 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one group 
Risk Factor 
Assessment 
Bias 9 Describe any efforts to address potential sources of bias Statistical Analyses 
Study size 10 Explain how the study size was arrived at Statistical Analyses 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and 
why 
Statistical Analyses 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding Statistical Analyses 
(b) Describe any methods used to examine subgroups and interactions Statistical Analyses 
(c) Explain how missing data were addressed Not applicable 
(d) If applicable, explain how loss to follow-up was addressed Not applicable 
(e) Describe any sensitivity analyses Statistical Analyses 
Results 
 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed 
eligible, included in the study, completing follow-up, and analysed 
Participants and 
Study Settings  
  (b) Give reasons for non-participation at each stage Participants and 
Study Settings  
  (c) Consider use of a flow diagram  
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential 
confounders 
Results; Tables 1 and 
2 
  (b) Indicate number of participants with missing data for each variable of interest  
  (c) Summarise follow-up time (eg, average and total amount) Results 
Outcome data 15* Report numbers of outcome events or summary measures over time Results 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for and why they were included 
Results; Table 3 
  (b) Report category boundaries when continuous variables were categorized Results; Table 3 
  (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period  
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Results; Table 4; 
Figure 
Discussion 
   
Key results 18 Summarise key results with reference to study objectives Discussion - 
Summary of main 
findings 
Limitations    
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence 
Discussion 
Generalisability 21 Discuss the generalisability (external validity) of the study results Discussion 
Other information 
   
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which 
the present article is based 
Page 12 
 
 
Appendix B: Association of serum paraoxonase-1 activity with incident type 2 diabetes using complex survey analyses 
PON-1 activity (U/L) Events/ 
Total 
Model 1  Model 2  Model 3  Model 4  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Per 1 SD increase 500 / 5,947 0.98 (0.89 to 1.08) 0.66 1.08 (0.98 to 1.18) 0.12 1.02 (0.93 to 1.13) 0.64 1.05 (0.95 to 1.15) 0.37 
Q1 (0.84-41-35) 104 / 1,190 ref  ref  ref  ref  
Q2 (41.36-49.67) 102 / 1,189 1.01 (0.76 to 1.36) 0.93 1.38 (1.01 to 1.90) 0.05 1.25 (0.91 to 1.70) 0.17 1.27 (0.93 to 1.74) 0.14 
Q3 (49.68-57.41) 106 / 1,190 1.11 (0.83 to 1.48) 0.49 1.33 (0.97 to 1.83) 0.07 1.21 (0.88 to 1.66) 0.23 1.27 (0.92 to 1.74) 0.14 
Q4 (57.42-68.96) 104 / 1,189 1.12 (0.84 to 1.49) 0.44 1.51 (1.10 to 2.07) 0.01 1.29 (0.94 to 1.76) 0.11 1.36 (0.99 to 1.87) 0.06 
Q5 (> 68.96) 84 / 1,189 0.87 (0.64 to 1.19)  0.39 1.30 (0.93 to 1.83) 0.12 1.12 (0.81 to 1.57) 0.49 1.21 (0.85 to 1.70) 0.29 
 
PON-1, paraoxonase-1; Q, quintile; SD, standard deviation 
Model 1: Age and sex 
Model 2: Model 1 plus fasting glucose, body mass index, systolic blood pressure, smoking status, alcohol consumption, and parental history of diabetes 
Model 3: Model 2 plus loge triglycerides, estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C 
equation), loge urinary albumin excretion and loge homeostasis model assessment of insulin resistance 
Model 4: Model 3 plus high-density lipoprotein cholesterol 
 
 
Appendix C: Association of serum high-density lipoprotein cholesterol with incident type 2 diabetes using complex survey analyses 
 
Serum HDL-cholesterol 
(mmol/l) 
Events/ 
Total 
Model 1  Model 2  Model 3  Model 4  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Per 1 SD increase 500 / 5,947 0.49 (0.42 to 0.56) < 0.01 0.67 (0.58 to 0.78) < 0.01 0.85 (0.72 to 1.00) 0.05 0.84 (0.71 to 0.99) 0.04 
Q1 (0.36-1.00) 200 / 1,237 ref  ref  ref  ref  
Q2 (1.01-1.19) 134 / 1,201 0.67 (0.53 to 0.85) 0.001 0.73 (0.56 to 0.95) 0.02 0.91 (0.69 to 1.21) 0.53 0.90 (0.68 to 1.19) 0.48 
Q3 (1.20-1.39) 75 / 1,178 0.38 (0.28 to 0.50) < 0.01 0.55 (0.41 to 0.74) < 0.01 0.75 (0.55 to 1.03) 0.075 0.74 (0.54 to 1.02) 0.06 
Q4 (1.40-1.65) 67 / 1,142 0.33 (0.24 to 0.45) < 0.01 0.59 (0.42 to 0.82) 0.002 0.88 (0.61 to 1.27) 0.49 0.86 (0.59 to 1.25) 0.43 
Q5 (≥ 1.66) 24 / 1,189 0.13 (0.08 to 0.20)  < 0.01 0.27 (0.17 to 0.45) < 0.01 0.48 (0.28 to 0.81) 0.006 0.46 (0.27 to 0.79) 0.005 
 
HDL, high-density lipoprotein; Q, quintile; SD, standard deviation 
Model 1: Age and sex 
Model 2: Model 1 plus fasting glucose, body mass index, systolic blood pressure, smoking status, alcohol consumption, and parental history of diabetes 
Model 3: Model 2 plus loge triglycerides, estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C 
equation), loge urinary albumin excretion, and loge homeostasis model assessment of insulin resistance 
Model 4: Model 3 plus paraoxonase-1 
 
 
